Business Wire

THERAMEX

20.10.2021 07:02:13 CEST | Business Wire | Press release

Share
Breaking the Silence in Osteoporosis

A new international survey of 1,008 women with osteoporosis from six countries, launched on World Osteoporosis Day, reveals that while more than two-thirds (67%) of women over the age of 55 mostly understand what osteoporosis is and the potential negative impact of future fractures, 19% felt poorly informed at the time of the diagnosis.1

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211019005894/en/

The survey initiated by Theramex in cooperation with the International Osteoporosis Foundation (IOF), was conducted in Germany, France, Italy, Spain, Australia, and Brazil. It included 316 postmenopausal women over the age of 55 years and 315 premenopausal women (40-55 years) with osteoporosis (altogether 62% of the surveyed women). Of these women, osteoporosis was only diagnosed after a fracture in almost 60% of the cases. This survey highlights a gap in osteoporosis awareness, as one-fourth of the patients aged 55 years and over were not aware and did not understand the link between osteoporosis and bone fractures.1 A third (35%) of respondents said they would have been motivated to watch out for their bone health if they had known that one in three women aged over 50 will suffer a fragility fracture, but fragility fractures are preventable with the right treatment.1,2 In addition, close to 25% of postmenopausal women felt not listened to by their doctors when discussing their treatment.1

Osteoporosis is a chronic condition causing loss of bone mass and strength, resulting in fragile bones.3 It is a growing problem,3 affecting around 500 million people globally.4 Osteoporosis affects more women than men, with the risk increasing with age.5 Women are at higher risk of osteoporosis after the menopause, when the ovaries stop producing oestrogen, a hormone which has a protective effect on bones.5

Dr. Philippe Halbout, International Osteoporosis Foundation CEO said, “The impact of osteoporosis should not be underestimated. Fractures can be life-altering, causing pain, disability and loss of independence which is why it’s so important to ensure that patients are receiving the information, care and treatment they need to manage their condition and prevent or delay fractures. This survey highlights the need for improved doctor-patient communications and demonstrates the importance of education to empower women to ask for more from their care.”

Theramex CEO, Robert Stewart, commented, “Women with osteoporosis deserve support and appropriate treatment to help them continue to enjoy their lifestyles and precious moments with loved ones. We are committed to working with the osteoporosis community to provide accessible information and education about the condition, as the more women know and understand, the more they will be empowered to ask for more from their osteoporosis care, helping to reduce or eliminate the risk of fractures.”

This World Osteoporosis Day, women are being urged to #askformore from their osteoporosis care and treatment. For further information and osteoporosis resources, visit www.worldosteoporosisday.org

ENDS

NOTES TO EDITOR:

About the survey1
The online survey was conducted among 1,008 women with osteoporosis across six countries: Germany (73), France (74), Spain (122), Italy (298), Australia (54) and Brazil (387). The respondents were all female with 377 under 40, 315 aged 40-54, 201 aged 55-64, 90 aged 65-75 and 25 over 75. It should be noted that the risk of osteoporosis increases with age, despite the number of women in the younger age category in this survey. The survey was conducted between 5 – 12 July 2021 by Opinion Matters on behalf of Theramex.

About Osteoporosis
Osteoporosis remains largely underdiagnosed and undertreated, resulting in a large number of fractures.

  • It is a significant health issue – affecting ~500 million people worldwide4
  • Osteoporosis affects more women than men and risk increase with age5
  • After the menopause women start to lose bone at a faster rate, raising the risk for women who have had an early menopause or hysterectomy5
  • One in three women aged over 50 will suffer a fragility fracture2
  • Hip, spine, and wrist fractures are the most common fractures in osteoporosis and have a debilitating impact on daily activities and quality of life2
  • After a spine fracture, mortality is increased immediately after the fracture event6
  • Spine fractures can lead to back pain, loss of height, deformity, immobility, impaired quality of life (QoL), and difficulties in activities of daily living7,8,9

About the International Osteoporosis Foundation (IOF)
The International Osteoporosis Foundation is the world’s largest non-governmental organization dedicated to the prevention, diagnosis, and treatment of osteoporosis and related musculoskeletal diseases.

IOF Vision
Our vision is a world without fragility fractures, in which healthy mobility is a reality for all.

IOF Mission
To promote bone and musculoskeletal health as a worldwide priority.

About Theramex
Theramex is a leading, global speciality pharmaceutical company dedicated to women and their health. With a broad portfolio of innovative and established brands covering contraception, fertility, menopause and osteoporosis, we support women at every stage of their lives. Our commitment is to listen and understand our patients, serve their needs, and offer healthcare solutions to help improve their lives. Our vision is to be a lifetime partner for women and the healthcare professionals who treat them, by providing innovative and effective solutions that care for and support women as they advance through each stage of their lives.

References:

  1. Opinion Matters. (2021) #Askformore Osteoporosis International Survey.
  2. Cooper, C. (2019) IOF Compendium of Osteoporosis . IOF. 2nd edition.
  3. Noh, J.Y., Yang, Y. & Jung, H. (2020) Int J Mol Sci. 21 (20), 7623
  4. IOF. (n.d.) IOF website Facts and Statistics https://www.osteoporosis.foundation/facts-statistics/epidemiology-of-osteoporosis-and-fragility-fractures [Accessed 18th October 2021]
  5. IOF. (n.d.) About Osteoporosis: Risk Factors. Available from: https://www.osteoporosis.foundation/patients/about-osteoporosis/risk-factors [Accessed 18th October 2021]
  6. Johnell, O. et al. (2004) Osteoporos Int 15 (1), 38-42.
  7. Nevitt, M.C. et al. (1998) Ann Intern Med 128 (10), 793-800.
  8. Lips, P. et al (1999) Osteoporos Int 10, 150-160.
  9. Tosteson, A.N. et al (2001) Osteoporos Int 12:1042-1049.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

SBC Medical Announces Pricing of Secondary Public Offering of 3.1 Million Shares of Common Stock20.4.2026 01:07:00 CEST | Press release

SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“the Company”), a Management Service Organization operating a wide range of franchise businesses across diverse medical fields, today announced the pricing of the underwritten secondary public offering of 3,100,000 shares of the Company’s common stock by Dr. Yoshiyuki Aikawa (the “Selling Stockholder”) at the public offering price of $3.25 per share. Additionally, the Selling Stockholder has granted the underwriters a 45-day option to purchase up to an additional 465,000 shares of the Company’s common stock. The offering is expected to close on or about April 21, 2026, subject to customary closing conditions. The Company is not selling any shares of its common stock in the offering. The Selling Stockholder will receive all of the proceeds from the offering. Maxim Group LLC is acting as the sole book-running manager and Roth Capital Partners is acting as the co-manager for the offering. The offering is being made pursuant to the Com

Horse Powertrain Reveals X-Range C15 Direct Drive Powertrain for Hybridizing BEV Platforms20.4.2026 01:01:00 CEST | Press release

Horse Powertrain, a global leader in innovative and low-emission powertrain systems, will unveil a new ‘all-in-one’ powertrain at Beijing Auto Show 2026: the X-Range C15 Direct Drive. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260419640202/en/ Left-facing view of the HORSE X-Range C15 Direct Drive The ultra-compact X-Range C15 Direct Drive integrates a full hybrid powertrain – including a 4-cylinder engine, transmission, power electronics, and an electric motor – into a single compact unit with a shared housing, designed to mount to the rear subframe enabling a double isolated installation for best NVH. The X-Range C15 Direct Drive is designed as an ‘all-in-one’ powertrain to replace the rear electric drive unit of an existing BEV platform. It enables an automaker to use a single shared platform for their BEV, HEV, PHEV, and REEV lineups without any significant changes to vehicle design or production environments. The ne

Compass Pathways Commends White House Executive Order to Accelerate Research and Access for Psychedelic Treatments18.4.2026 22:12:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, welcomes the White House Executive Order on accelerating medical treatments for serious mental illness. “We commend the Administration’s Executive Order on psychedelic treatment which recognizes the profound urgency of the mental health crisis facing millions of Americans and the potential impact FDA-approved psychedelics could have,” said Kabir Nath, CEO at Compass Pathways. “Today’s announcement aligns regulatory urgency with patient need, and we applaud the Administration for taking this important step forward in accelerating access, without compromising rigorous science. Compass is conducting the largest, most robust classic psychedelic studies to date with COMP360 synthetic psilocybin. We have recently reported two positive phase 3 trials in treatment-resistant depression (TRD) with highly statistically significant and clinically meaningful data that

2026 NAB Show Opens Tomorrow, Uniting Global Media Leaders to Shape the Future of Storytelling18.4.2026 04:08:00 CEST | Press release

CEO of Zhong, one of YouTube’s most-watched creators with 70 million subscribers and 95 million followers on all platforms, joins program The 2026 NAB Show kicks off Saturday, April 18, with the show floor and exhibits opening on April 19, highlighting the most innovative companies and bringing together the world’s most influential voices across media, entertainment and technology for the industry’s premier global event. As the only platform that convenes broadcasters, media companies, content creators and technology innovators at scale, NAB Show continues its century-long legacy as the catalyst for innovation, growth and deal-making in a rapidly evolving, multi-platform world. From artificial intelligence and the creator economy to sports, streaming and cloud transformation, NAB Show is where the tools, talent and ideas driving the future of storytelling converge. “NAB Show is where the global media ecosystem comes together not just to explore what’s next—but to build it,” said Karen

Philip Morris International Announces U.S. FDA Reauthorization of IQOS as a Modified Risk Tobacco Product17.4.2026 23:43:00 CEST | Press release

A pioneer in smoke-free tobacco products, Philip Morris International is the only company that has received modified risk tobacco product authorizations for heated tobacco products.In their order, FDA concluded that: “Scientific studies have shown that switching completely from conventional cigarettes to the IQOS system significantly reduces your body’s exposure to harmful or potentially harmful chemicals” The U.S. Food and Drug Administration (FDA) announced that it has authorized the renewal of modified risk tobacco product (MRTP) orders previously granted to PMI for two versions of the IQOS device and three variants of the tobacco consumables, commercialized under the HEETS brand. This renewal allows PMI to continue sharing reduced-exposure information with U.S. adults 21+ who use traditional tobacco products, such as combustible cigarettes. The agency concluded that renewing the IQOS and HEETS MRTP authorizations is appropriate to promote public health and is expected to benefit th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye